Research Articles
First-Pass Metabolism of Omeprazole in Rats

https://doi.org/10.1002/jps.2600830812Get rights and content

Abstract

To clarify the in vivo first-pass metabolism of omeprazole, the pharmacokinetics were examined after oral, intraduodenal (id), intraportal venous (ipv), and intravenous (iv) administration at various doses to rats. Extraction ratios in the liver and intestinal tract were determined from the areas under the concentration-time curve (AUC) for ipv and iv administration and from those for id and ipv administration, respectively. Assuming that the drug was absorbed from the gastrointestinal tract completely, the hepatic and intestinal extraction ratios were 0.80, 0.63, and 0.59 at doses of 2.5, 5, and 10 mg/kg and 0.70 and 0.73 at doses of 5 and 10 mg/kg, respectively. The bioavailability of orally administered omeprazole was 6.4, 9.6, and 12.6% at the doses of 10, 20, and 40 mg/kg, respectively. There were no differences in the distribution volume of steady state, total clearance, or elimination half-life at any doses. In addition, the AUC value after oral administration (20 mg/kg) in rats acutely intoxicated with CCI4 was 2.4 times larger than that in the control. These findings suggest that omeprazole undergoes a first-pass metabolism in the intestinal mucosa and/or lumen, as well as in the liver, and that the major contribution to the dose-dependent increase in bioavailability is a saturation of the first-pass metabolism in the liver.

References and Notes (20)

  • A. Blanchi et al.

    Lancet

    (1982)
  • K. Öberg et al.

    Lancet

    (1983)
  • W. Londong et al.

    Gastroenterology

    (1983)
  • L.K. Webster et al.

    Biochem. Pharmacol.

    (1985)
  • E. Fellenius et al.

    Nature

    (1981)
  • B. Wallmark et al.

    Scand. J. Gastroenterol.

    (1985)
  • R.N. Brogden et al.

    Drugs

    (1982)
  • M. Classen et al.

    Deutsche Med. Wochen.

    (1985)
  • M. Classen et al.

    Deutsche Med. Wochen.

    (1985)
  • K. Lauritsen et al.

    Engl. J. Med.

    (1985)
There are more references available in the full text version of this article.

Cited by (48)

  • The natural flavonoid myricetin inhibits gastric H<sup>+</sup>, K<sup>+</sup>-ATPase

    2018, European Journal of Pharmacology
    Citation Excerpt :

    Additionally, myricetin is easily converted into various derivatives after being taken up by the body (Lin et al., 2012). In contrast, the reported bioavailability of omeprazole is 9.6–70% in human and experimental animals (Larsson et al., 1983; Stedman and Barclay, 2000; Watanabe et al., 1994). Proton pump inhibitors, including omeprazole, are widely used for the clinical treatment of gastric acid-related disorders (Schubert, 2010), but recent studies indicate that these inhibitors increase the risk of other diseases, including cardiovascular events (Cardoso et al., 2015), bone fracture (Leontiadis and Moayyedi, 2014), infection (Sultan et al., 2008), chronic kidney disease (Klatte et al., 2017), and dementia (Goldstein et al., 2017).

  • Oxidation and reduction of omeprazole on boron-doped diamond electrode: Mechanistic, kinetic and sensing performance studies

    2017, Sensors and Actuators, B: Chemical
    Citation Excerpt :

    Pharmaceutical formulations of omeprazole are available as tablets and capsules (containing pure omeprazole or its magnesium salt) or a powder (sodium salt of omeprazole) for intravenous applications. The most of OMZ pharmaceutical formulations for oral use are enteric-coated, due to rapid degradation of the tablet or capsule only in the acidic media of the stomach [4]. For the determination of OMZ in pharmaceutical and biological samples several analytical methods have been developed.

  • Instantaneous enteric nano-encapsulation of omeprazole: Pharmaceutical and pharmacological evaluation

    2014, International Journal of Pharmaceutics
    Citation Excerpt :

    Omeprazole seems to be well absorbed from the gastrointestinal tract (GIT). However, its oral bioavailability in humans is about 40–50% due to a marked first-pass metabolism before entering the systemic circulation (Watanabe et al., 1994). Omeprazole is widely used in doses of 20–80 mg in treatment of duodenal and gastric ulcers, reflux oesophagitis and in the Zollinger–Ellison Syndrome (Clissold and Campoli-Richards, 1986; Watanabe et al., 1994).

View all citing articles on Scopus
View full text